Global pharmaceutical giant AstraZeneca is gearing up to launch at least 100 new medicines in China over the next five years! 😮✨ This ambitious plan was shared by Sharon Barr, EVP of Biopharmaceuticals R&D at AstraZeneca, in a recent interview with CGTN.
Leveraging the innovative brilliance of its Shanghai R&D center, AstraZeneca is collaborating closely with Chinese partners to bring cutting-edge treatments to patients. 🌐🤝 Barr emphasized the company's dedication to tapping into local talent and resources to drive medical breakthroughs.
\"We see immense potential in the Chinese mainland,\" Barr noted. \"By working hand-in-hand with our collaborators here, we're not only advancing healthcare but also fostering mutual growth and success.\" 🌱💡
This exciting development highlights China's growing role in the global pharmaceutical scene. Stay tuned, because these new medicines could be game-changers! 🩺💊
Reference(s):
AstraZeneca EVP: Explore mutual interests with Chinese collaborators
cgtn.com
